Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phenazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenazine SCHEMBL8940300 | 0.84 | ALDH1A1 (0.52) | MAPTALDH1A1SMN1; SMN2HPGDHSD17B10 | |
| Cadaverine Tartrate SCHEMBL29594030 | 0.82 | KDM4E (0.44) | MAPTALDH1A1SMN1; SMN2HPGDHSD17B10 | |
| Cadaverine Tartrate SCHEMBL27323460 | 0.82 | KDM4E (0.44) | MAPTALDH1A1SMN1; SMN2HPGDHSD17B10 | |
| Cadaverine Tartrate SCHEMBL3454249 | 0.82 | KDM4E (0.44) | MAPTALDH1A1SMN1; SMN2HPGDHSD17B10 | |
| Cadaverine Tartrate SCHEMBL3454252 | 0.82 | KDM4E (0.44) | MAPTALDH1A1SMN1; SMN2HPGDHSD17B10 | |
| Phenazine SCHEMBL6213173 | 0.82 | MAPT (0.69) | MAPTALDH1A1SMN1; SMN2HPGDHSD17B10 | |
| Cadaverine Tartrate SCHEMBL5874237 | 0.80 | ALDH1A1 (0.63) | MAPTALDH1A1SMN1; SMN2HPGDHSD17B10 | |
| Cadaverine Tartrate SCHEMBL28081412 | 0.80 | ALDH1A1 (0.63) | MAPTALDH1A1SMN1; SMN2HPGDHSD17B10 | |
| Cadaverine Tartrate SCHEMBL5874249 | 0.80 | ALDH1A1 (0.63) | MAPTALDH1A1SMN1; SMN2HPGDHSD17B10 | |
| Phenazine SCHEMBL182948 | 0.79 | MAPT (0.85) | MAPTALDH1A1SMN1; SMN2HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113388007-A | Ultra-pure agonists of guanylate cyclase C, methods of making and using the same | 博士医疗爱尔兰有限公司 | 2021-09-14 | — | — | CN | disclosed |
| CN-105764916-B | Ultra-pure agonists of guanylate cyclase C, methods of making and using the same | 博士医疗爱尔兰有限公司 | 2021-05-18 | — | — | CN | disclosed |
| CN-105963676-B | Agonists of guanylate cyclase for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstones, obesity and other cardiovascular diseases | 药物协和股份有限公司 | 2020-02-18 | — | — | CN | disclosed |
| CN-108676076-A | The method for preparing guanosine cyclic mono-phosphate agonist | 辛纳吉制药公司 | 2018-10-19 | — | — | CN | disclosed |
| CN-107090016-A | The method for preparing guanosine cyclic mono-phosphate activator | 辛纳吉制药公司 | 2017-08-25 | — | — | CN | disclosed |
| CN-105963676-A | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases | 药物协和股份有限公司 | 2016-09-28 | — | — | CN | disclosed |
| CN-102858361-B | Agonists of guanylate cyclase for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstones, obesity and other cardiovascular diseases | 药物协和股份有限公司 | 2016-08-03 | — | — | CN | disclosed |
| CN-105764916-A | Ultra-pure agonists of guanylate cyclase C, methods of making and using the same | 辛纳吉制药公司 | 2016-07-13 | — | — | CN | disclosed |
| CN-103764672-A | Process for preparing guanylate cyclase C agonists | SYNERGY PHARMACEUTICALS INC | 2014-04-30 | — | — | CN | disclosed |
| CN-102858361-A | Agonists of guanylate cyclase for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstones, obesity and other cardiovascular diseases | SYNERGY PHARMACEUTICALS INC | 2013-01-02 | — | — | CN | disclosed |